Teserpaturev is a Oncolytic Virus owned by Daiichi Sankyo, and is involved in 1 clinical trial, which is ongoing.

DS1647(G-47 Delta) is a genetically engineered HSV-1 with triple mutations that expresses augmented viral replication in tumor cells, strong induction of anti-tumor immunity and enhanced safety in normal tissues. HSV-1 incorporates large and/or multiple transgenes within the viral genome. A virocentric point of view considers the direct lysis of tumor cells by the oncolytic virus as the most important parameter for efficacy. Immunocentrics consider that the lysis of tumor cells is important as long as it can activate an immune response against the tumor. For virocentrics it is important to inhibit the immune response, for immunocentrics is important to boost it even it will neutralize the virus. A combination of these two mechanisms contributes to virotherapy with more or less success depending on the architecture and immunogenicity of each tumor.

The revenue for Teserpaturev is expected to reach a total of $1.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Teserpaturev NPV Report.

Teserpaturev was originated by Daiichi Sankyo and University of Tokyo and is currently owned by Daiichi Sankyo.

Teserpaturev Overview

Teserpaturev (Delytact) is a genetically engineered herpes simplex virus type 1 (HSV-1) with triple mutations that expresses augmented viral replication in tumor cells, strong induction of anti-tumor immunity and enhanced safety in normal tissues. It is formulated as solution for intratumor route of administration. Delytact is indicated for the treatment of patients with malignant glioma or any type of primary brain cancer.

Teserpaturev is under investigation for progressive olfactory neuroblastoma and malignant pleural mesothelioma. G-47 Delta was also under investigation for the treatment of recurrent glioblastoma, castration resistant prostate cancer, breast cancer, schwannoma renal carcinoma, and urothelial carcinoma. G-47 Delta is administered by intratumoral route. G-47 Delta is a third generation oncolytic herpes simplex virus type 1 (HSV-1). HSV-1 is the prototype of the a-herpes virus family. G-47 Delta is a triple-mutated, third-generation oncolytic HSV-1 which is developed by introducing an additional genetic mutation to the viral genome of G207, a second generation HSV-1. 

Daiichi Sankyo Overview

Daiichi Sankyo is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY1,044,892 million for the fiscal year ended March 2022 (FY2022), an increase of 8.6% over FY2021. In FY2022, the company’s operating margin was 7.1%, compared to an operating margin of 7% in FY2021. In FY2022, the company recorded a net margin of 6.4%, compared to a net margin of 7.9% in FY2021. The company reported revenues of JPY327,480 million for the second quarter ended September 2022, an increase of 16.8% over the previous quarter.

Quick View – Teserpaturev

Report Segments
  • Innovator (NME)
Drug Name
  • Teserpaturev
Administration Pathway
  • Intratumor
Therapeutic Areas
  • Non Malignant Disorders
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.